Respiratory MedicineRespiratory diseases are increasing in prevalence and mortality, and today are the third-leading cause of death in the U.S. The DCRI’s Respiratory Research program includes physicians with first-hand experience treating patients with diverse respiratory problems and expertise in conducting clinical and translational research in patient populations with respiratory disease.
Faculty are drawn from the Duke University School of Medicine’s division of pulmonary and critical care medicine, consistently ranked among the top 10 programs in the United States.
A Pragmatic Approach to Respiratory Research
Respiratory research at the DCRI is distinguished by world-class faculty leading cutting-edge programs in airway biology, environmental-health sciences, and lung fibrosis. Our team has coordinated multicenter trials in pulmonary diseases, including idiopathic pulmonary fibrosis (IPF) and lung transplantation. And through Duke, we’re connected to one of the largest and most successful lung-transplant programs in North America. We’re trained physicians and trained researchers who understand the biology of the disease because we care for the patient population every day. Our investigators have pioneered new and pragmatic approaches to obtain clinical data for registry and trial studies improving study efficiency and data quality.
Respiratory Disease Trial Experience
The DCRI Respiratory team has advanced training in study design, biostatistics, regulatory affairs, and clinical trials. It also has specific expertise in:
- Acute respiratory distress syndrome
- Chronic obstructive pulmonary disease (COPD)
- Cystic fibrosis
- Hyperbaric medicine
- Idiopathic pulmonary fibrosis (IPF)
- Interventional pulmonology
- Lung cancer
- Lung injury following bone marrow transplantation
- Lung transplantation
- Pediatric lung disease
- Pulmonary hypertension
Our Respiratory faculty consists of members of Duke University School of Medicine’s Division of Pulmonary and Critical Care Medicine, an institution that consistently ranks among the top-10 programs in the United States. These faculty members have hands-on experience treating patients with diverse respiratory problems and offer expertise in conducting clinical and translational research in patient populations with respiratory disease.
Watch the following videos to learn more about how DCRI Respiratory Medicine's Scott Palmer, MD, and Jamie Todd, MD, are directing therapies and discovering new treatments for idiopathic pulmonary fibrosis through innovative registries and genetics research.
Jamie Todd, MDAssistant Professor, DCRI Respiratory
“We’re on the cusp of a decade or two of promise – where we can go from these observations in the lab to really bringing meaningful treatment back to patients.”
National Heart, Lung, and Blood Institute (NHLBI)
- Lung Regeneration and Repair Consortium (LRRC)
- Molecular Atlas of Lung Development—Data Coordinating Center
National Institute of Allergy Immunology and Infectious Disease
- The Lung Transplant Clinical Trials Network (LT-CTN)
- Obesity, Inflammation, and Lung Injury after Lung Transplantation
Centers for Disease Control
- Proteomics of Flavorings-Induced Airway Disease
- Phase II Study of Safety and Efficacy in Subjects with Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim Corporation
- Idiopathic Pulmonary Fibrosis—PROspective Outcomes (IPF-PRO) Registry
The Biomarker Factory
- Cross-Sectional Blood Banking and Processing
at the DCRI
Scott M. Palmer leads a successful program of clinical, basic and translational research in transplantation and advanced lung diseases. He currently directs the respiratory research program at the DCRI and serves as Vice Chair for Research in the Department of Medicine.
Palmer has more than 150 peer reviewed publications, received numerous awards, including election into the American Society for Clinical Investigation (ASCI) in 2012, chaired many sessions at national and international meetings, serves regularly on NIH study sections, and is on the editorial board of many prominent journals. He is also Associate Director of the Clinical Research Training Program at Duke and has personally mentored over 40 pre-and post-doctoral trainees, many of whom are now engaged in their own successful research careers.
His scientific accomplishments include the first human studies to demonstrate the importance of innate immunity in transplant rejection and completion of a prospective multicenter study that improved CMV prevention after lung transplantation.